Fate Therapeutics Stock Performance
| FATE Stock | USD 1.21 0.10 7.63% |
Fate Therapeutics has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.89, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Fate Therapeutics will likely underperform. Fate Therapeutics right now shows a risk of 4.65%. Please confirm Fate Therapeutics skewness, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Fate Therapeutics will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Fate Therapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Fate Therapeutics may actually be approaching a critical reversion point that can send shares even higher in February 2026. ...more
1 | Fate Therapeutics Q3 Earnings Snapshot | 11/13/2025 |
2 | New release When Fate Called Their Name tells a tale of youth, loyalty, and the hidden cost of war | 11/21/2025 |
3 | Gulf Coast Commercial Group, Nexus Real Estate Co. Partner to Develop Kroger-Anchored Shopping Center in Fate | 12/04/2025 |
4 | Fate Therapeutics Inc Stock Analysis and Forecast - Market Profile Overview Fast Profit Portfolio Plans - earlytimes.in | 12/09/2025 |
5 | Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635 | 01/05/2026 |
6 | Trend Review Why Fate Therapeutics Inc stock could outperform in 2025 - Layoff News Technical Buy Zone Confirmation - moha.gov.vn | 01/08/2026 |
7 | Disposition of 5190 shares by Bahram Valamehr of Fate Therapeutics at 1.0708 subject to Rule 16b-3 | 01/09/2026 |
8 | Acquisition by Bahram Valamehr of 335000 shares of Fate Therapeutics subject to Rule 16b-3 | 01/15/2026 |
9 | Acquisition by Adawi Kamal of 75000 shares of Fate Therapeutics at 1.05 subject to Rule 16b-3 | 01/16/2026 |
10 | Acquisition by Lee Michael Stewart of 55000 shares of Fate Therapeutics at 1.32 subject to Rule 16b-3 | 01/26/2026 |
| Begin Period Cash Flow | 41.9 M | |
| Total Cashflows From Investing Activities | 12.2 M |
Fate Therapeutics Relative Risk vs. Return Landscape
If you would invest 129.00 in Fate Therapeutics on October 30, 2025 and sell it today you would earn a total of 2.00 from holding Fate Therapeutics or generate 1.55% return on investment over 90 days. Fate Therapeutics is currently generating 0.1314% in daily expected returns and assumes 4.6522% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than Fate, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Fate Therapeutics Target Price Odds to finish over Current Price
The tendency of Fate Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.21 | 90 days | 1.21 | about 27.43 |
Based on a normal probability distribution, the odds of Fate Therapeutics to move above the current price in 90 days from now is about 27.43 (This Fate Therapeutics probability density function shows the probability of Fate Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.89 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Fate Therapeutics will likely underperform. Additionally Fate Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Fate Therapeutics Price Density |
| Price |
Predictive Modules for Fate Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Fate Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Fate Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Fate Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Fate Therapeutics is not an exception. The market had few large corrections towards the Fate Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Fate Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Fate Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.22 | |
β | Beta against Dow Jones | 1.89 | |
σ | Overall volatility | 0.15 | |
Ir | Information ratio | -0.03 |
Fate Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Fate Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Fate Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Fate Therapeutics may become a speculative penny stock | |
| Fate Therapeutics had very high historical volatility over the last 90 days | |
| Fate Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 13.63 M. Net Loss for the year was (186.26 M) with loss before overhead, payroll, taxes, and interest of (92.41 M). | |
| Fate Therapeutics currently holds about 568.85 M in cash with (122.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Fate Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 79.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Lee Michael Stewart of 55000 shares of Fate Therapeutics at 1.32 subject to Rule 16b-3 |
Fate Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Fate Stock often depends not only on the future outlook of the current and potential Fate Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Fate Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 113.7 M | |
| Cash And Short Term Investments | 279.1 M |
Fate Therapeutics Fundamentals Growth
Fate Stock prices reflect investors' perceptions of the future prospects and financial health of Fate Therapeutics, and Fate Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fate Stock performance.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (19.95) % | ||||
| Current Valuation | 14.94 M | ||||
| Shares Outstanding | 115.35 M | ||||
| Price To Earning | (4.35) X | ||||
| Price To Book | 0.65 X | ||||
| Price To Sales | 21.17 X | ||||
| Revenue | 13.63 M | ||||
| Gross Profit | (92.41 M) | ||||
| EBITDA | (176.58 M) | ||||
| Net Income | (186.26 M) | ||||
| Cash And Equivalents | 568.85 M | ||||
| Cash Per Share | 5.86 X | ||||
| Total Debt | 85.27 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 6.55 X | ||||
| Book Value Per Share | 2.03 X | ||||
| Cash Flow From Operations | (122.87 M) | ||||
| Earnings Per Share | (1.33) X | ||||
| Market Capitalization | 151.11 M | ||||
| Total Asset | 440.69 M | ||||
| Retained Earnings | (1.4 B) | ||||
| Working Capital | 253.39 M | ||||
| Current Asset | 47.4 M | ||||
| Current Liabilities | 14.68 M | ||||
About Fate Therapeutics Performance
By analyzing Fate Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Fate Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Fate Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Fate Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.47) | (0.49) | |
| Return On Assets | (0.38) | (0.40) | |
| Return On Equity | (0.67) | (0.71) |
Things to note about Fate Therapeutics performance evaluation
Checking the ongoing alerts about Fate Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Fate Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Fate Therapeutics may become a speculative penny stock | |
| Fate Therapeutics had very high historical volatility over the last 90 days | |
| Fate Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 13.63 M. Net Loss for the year was (186.26 M) with loss before overhead, payroll, taxes, and interest of (92.41 M). | |
| Fate Therapeutics currently holds about 568.85 M in cash with (122.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Fate Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 79.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Lee Michael Stewart of 55000 shares of Fate Therapeutics at 1.32 subject to Rule 16b-3 |
- Analyzing Fate Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fate Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Fate Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Fate Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fate Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Fate Therapeutics' stock. These opinions can provide insight into Fate Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Fate Stock analysis
When running Fate Therapeutics' price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |